Search - tctmd.com

Displaying 561 - 580 of 642

Sort: Relevancy | Date

News Daily News

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

Jason Kahn

March 06, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

News Daily News

Statins Reduce Late Restenosis After SES Implantation

Jason Kahn

March 05, 2012

News Daily News

EVOLVE Published: Bioabsorbable EES Matches Permanent-Polymer Version

February 21, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation

Very Late Coronary Stent Thrombosis of a Newer Generation EES vs. Early Generation DES

Presenter: L. Raber

February 06, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

Presentation

Very Late Stent Thrombosis and Late TLR After Sirolimus-Eluting Stent Implantation

Presenter: Takeshi Kimura

January 08, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Jason Kahn

January 08, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Presentation TCT 2012

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Presenter: Kyounghoon Lee, Tae Hoon Ahn, Soon Yong Suh, Woong Chol Kang, Seung Hwan Han, Eak Kyun Shin

January 03, 2012

Presentation TCT 2012

Evaluation of second generation DES in an ex-vivo model of stent thrombosis

Presenter: Alexander Sheehy, Leigh B. Kleinert, Stephen Pacetti, Syed Hossainy, Mikael Trollsas, Stuart K. Williams

January 03, 2012

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

News Conference News

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Yael L. Maxwell

November 30, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Conference News

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

November 21, 2011

News Conference News

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

November 20, 2011

News Conference News

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

November 16, 2011

Advertisement

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Statins Reduce Late Restenosis After SES Implantation

EVOLVE Published: Bioabsorbable EES Matches Permanent-Polymer Version

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Very Late Coronary Stent Thrombosis of a Newer Generation EES vs. Early Generation DES

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Very Late Stent Thrombosis and Late TLR After Sirolimus-Eluting Stent Implantation

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

SCAAR: Second-Generation DES Improve Hard Outcomes

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Evaluation of second generation DES in an ex-vivo model of stent thrombosis

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Stent Thrombosis Linked to Uncovered, Malapposed Stent Struts

Paclitaxel-Eluting Bioabsorbable Stent Shows Advantage over Bare-Metal Version

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content